JP4269144B2 - 自己免疫疾患および炎症障害の処置のためのトリプトリドアナログ - Google Patents

自己免疫疾患および炎症障害の処置のためのトリプトリドアナログ Download PDF

Info

Publication number
JP4269144B2
JP4269144B2 JP2002532445A JP2002532445A JP4269144B2 JP 4269144 B2 JP4269144 B2 JP 4269144B2 JP 2002532445 A JP2002532445 A JP 2002532445A JP 2002532445 A JP2002532445 A JP 2002532445A JP 4269144 B2 JP4269144 B2 JP 4269144B2
Authority
JP
Japan
Prior art keywords
hydrogen
cycloalkyl
independently selected
aryl
natural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002532445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525082A5 (https=
JP2004525082A (ja
Inventor
ハリハラン ベンカテサン，
ジェイムズ ピー． スナイダー，
デニス シー． リオッタ，
スシェン ワン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of JP2004525082A publication Critical patent/JP2004525082A/ja
Publication of JP2004525082A5 publication Critical patent/JP2004525082A5/ja
Application granted granted Critical
Publication of JP4269144B2 publication Critical patent/JP4269144B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/04—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/001—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain
    • C07C37/002—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain by transformation of a functional group, e.g. oxo, carboxyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/14—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/32—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2002532445A 2000-10-02 2001-10-02 自己免疫疾患および炎症障害の処置のためのトリプトリドアナログ Expired - Fee Related JP4269144B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23755700P 2000-10-02 2000-10-02
PCT/US2001/030951 WO2002028862A2 (en) 2000-10-02 2001-10-02 Triptolide analogs for the treatment of autoimmune and inflammatory disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008331610A Division JP2009102371A (ja) 2000-10-02 2008-12-25 自己免疫疾患および炎症障害の処置のためのトリプトリドアナログ

Publications (3)

Publication Number Publication Date
JP2004525082A JP2004525082A (ja) 2004-08-19
JP2004525082A5 JP2004525082A5 (https=) 2008-07-17
JP4269144B2 true JP4269144B2 (ja) 2009-05-27

Family

ID=22894243

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002532445A Expired - Fee Related JP4269144B2 (ja) 2000-10-02 2001-10-02 自己免疫疾患および炎症障害の処置のためのトリプトリドアナログ
JP2008331610A Pending JP2009102371A (ja) 2000-10-02 2008-12-25 自己免疫疾患および炎症障害の処置のためのトリプトリドアナログ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008331610A Pending JP2009102371A (ja) 2000-10-02 2008-12-25 自己免疫疾患および炎症障害の処置のためのトリプトリドアナログ

Country Status (8)

Country Link
US (3) US6777441B2 (https=)
EP (2) EP1330459B1 (https=)
JP (2) JP4269144B2 (https=)
AT (2) ATE469907T1 (https=)
AU (2) AU9654201A (https=)
CA (1) CA2424555A1 (https=)
DE (2) DE60121986T2 (https=)
WO (1) WO2002028862A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028862A2 (en) 2000-10-02 2002-04-11 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP2468277A1 (en) * 2002-05-31 2012-06-27 Pharmagenesis, Inc. Triptolide derivatives for modulation of apoptosis and immunosuppression
WO2004023984A2 (en) * 2002-09-13 2004-03-25 Smith C Steven Novel composition and method for treatment of upper respiratory conditions
TW200509958A (en) * 2003-02-14 2005-03-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2005012294A1 (en) * 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
US20050192261A1 (en) * 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
WO2005062913A2 (en) * 2003-12-24 2005-07-14 Pharmagenesis, Inc. Triplide 5,6-derivatives as immunomodulators and anticancer agents
EP1722806A4 (en) * 2004-02-09 2009-09-16 Pharmagenesis Inc METHOD OF ISOLATING TRIPTOLIDE COMPOUNDS FROM TRIPTERYGIUM WILFORDII
WO2005084365A2 (en) * 2004-03-02 2005-09-15 Pharmagenesis, Inc. Triptolide lactone ring derivatives as immunomodulators and anticancer agents
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2006012204A2 (en) * 2004-06-25 2006-02-02 Pharmagenesis, Inc. Method for treatment of inflammatory disorders using triptolide compounds
WO2006044496A2 (en) * 2004-10-13 2006-04-27 Pharmagenesis, Inc. Identification and screening of triptolide target molecules
WO2007053844A2 (en) * 2005-10-31 2007-05-10 Rigel Pharmaceuticals, Inc. Compositions and methods for treating inflammatory disorders
EP2240460A4 (en) * 2008-01-07 2012-02-22 Univ Emory BRANCHED DIEPXYDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
US8147882B2 (en) 2009-09-30 2012-04-03 Leonard Lomax Herbal pain killer compositions
CN104478832B (zh) * 2015-01-05 2016-04-20 项敬来 二萜化合物，含其的药物组合物及其制备方法和应用
JP6743135B2 (ja) * 2015-09-02 2020-08-19 アッヴィ・インコーポレイテッド 抗ウィルス性テトラヒドロフラン誘導体

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1179866A (en) * 1967-09-08 1970-02-04 Agfa Gevaert Nv Photopolymerisation of Ethylenically Unsaturated Organic Compounds
US3917652A (en) * 1968-04-29 1975-11-04 Hoffmann La Roche Juvabione and derivatives thereof
BE789948A (fr) * 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
US3816437A (en) * 1972-12-22 1974-06-11 Sandoz Ag Thieno(2,3-g)indazoles
US3957816A (en) * 1973-01-31 1976-05-18 Sandoz, Inc. Substituted naphtho pyrazoles
JPS5473766A (en) 1977-11-21 1979-06-13 Nippon Terpen Kagaku Kk Manufacture of menthofuran
GB2104516B (en) 1981-07-13 1985-12-04 Univ Brunel M-alkylphenol derivatives and their use in copper extraction
DE3219048A1 (de) 1982-05-21 1983-11-24 Basf Ag, 6700 Ludwigshafen Thermoplastische formmassen
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3440826A1 (de) 1983-11-10 1985-05-23 Basf Ag, 6700 Ludwigshafen 1,1-ethanoretinsaeuren und ihre c(pfeil abwaerts)1(pfeil abwaerts)-c(pfeil abwaerts)4(pfeil abwaerts)-alkylester
JPS61197573A (ja) 1985-02-26 1986-09-01 Chugai Pharmaceut Co Ltd ５，６−エポキシ化トランスビタミンｄ３
JP2865211B2 (ja) 1988-09-15 1999-03-08 ファルマシア・アンド・アップジョン・カンパニー ５’―インドリニル―５β―アミドメチルオキサゾリジン―２―オン類、３―（縮合環置換）フェニル―５β―アミドメチルオキサゾリジン―２―オン類および３―（窒素原子置換）フェニル―５β―アミドメチルオキサゾリジン―２―オン類
DE3913310A1 (de) 1989-04-20 1990-10-25 Schering Ag Spirocyclopropane in der vitamin d-reihe
JPH03197464A (ja) 1989-12-16 1991-08-28 Basf Ag 置換アゾリルメチルシクロアルカノール及びこれを含有する殺菌剤
US5430054A (en) * 1989-12-22 1995-07-04 Jiangsu Family Planning Institute Preparation methods of diterpene lactone compounds and application of the same to antifertility
AU7570191A (en) * 1990-03-14 1991-10-10 Board Of Regents, The University Of Texas System Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
US5216175A (en) * 1990-03-23 1993-06-01 Sri International Antimalarial analogs of artemisinin
US5581004A (en) * 1991-09-23 1996-12-03 Board Of Regents Of The University Of Nebraska Preparation and use of (2-butene-1,4-diyl) magnesium complexes in organic synthesis
AU2466092A (en) 1992-07-22 1994-02-14 Michael F. Lucey Highly filled polymeric compositions
WO1994026265A1 (en) * 1993-05-06 1994-11-24 Pharmagenesis, Inc. 16-hydroxytriptolide composition and method for immunotherapy
FR2707992B1 (fr) 1993-07-21 1995-10-13 Flamel Tech Sa Nouveaux produits organiques contenant des fonctions thiols réactives, l'un de leurs procédés de préparation et les biomatériaux les contenant.
GB9325415D0 (en) 1993-12-13 1994-02-16 Res Inst Medicine Chem Chemical compounds
GB9405715D0 (en) 1994-03-23 1994-05-11 Res Inst Medicine Chem Chemical compounds
FR2733498B1 (fr) * 1995-04-27 1997-05-30 Adir Nouveaux composes cyclohexaniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5723632A (en) * 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
IT1287174B1 (it) 1996-11-15 1998-08-04 Angelini Ricerche Spa Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
US5972998A (en) * 1997-05-23 1999-10-26 Hoechst Marion Roussel, Inc. Triptolide derivatives useful in the treatment of autoimmune diseases
WO1999019298A1 (en) 1997-10-14 1999-04-22 The Scripps Research Institute iso-CBI AND iso-CI ANALOGS OF CC-1065 AND THE DUOCARMYCINS
NZ504884A (en) 1997-12-08 2002-10-25 Scripps Research Inst Synthesis of the dihydroindole C-ring of CC-1065/duocarmycin analogs and certain intermediates
DE19855859A1 (de) * 1998-12-03 2000-06-08 Degussa Katalysatoren für die enantioselektive Epoxidierung von C=C-Doppelbindungen
FR2787451B1 (fr) * 1998-12-18 2001-01-26 Adir Nouveaux composes imidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR023071A1 (es) 1998-12-23 2002-09-04 Syngenta Participations Ag Compuestos de piridincetona, compuestos intermediarios, composicion herbicida e inhibidora del crecimiento de plantas, metodo para controlar la vegetacion indeseada, metodo para inhibir el crecimiento de las plantas, y uso de la composicion para controlar el crecimiento indeseado de plantas.
US6331642B1 (en) 1999-07-12 2001-12-18 Hoffmann-La Roche Inc. Vitamin D3 analogs
WO2002028862A2 (en) * 2000-10-02 2002-04-11 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
US20040204394A1 (en) * 2003-04-11 2004-10-14 Aderis Pharmaceuticals, Inc. Triptolide analogues

Also Published As

Publication number Publication date
AU9654201A (en) 2002-04-15
WO2002028862A2 (en) 2002-04-11
US8193249B2 (en) 2012-06-05
WO2002028862A3 (en) 2002-09-12
ATE334986T1 (de) 2006-08-15
DE60121986D1 (de) 2006-09-14
JP2004525082A (ja) 2004-08-19
DE60142313D1 (de) 2010-07-15
US20060040907A1 (en) 2006-02-23
EP1659125A1 (en) 2006-05-24
DE60121986T2 (de) 2007-07-26
AU2001296542B9 (en) 2002-04-15
CA2424555A1 (en) 2002-04-11
US7557139B2 (en) 2009-07-07
AU2001296542B2 (en) 2007-10-25
JP2009102371A (ja) 2009-05-14
US20030027806A1 (en) 2003-02-06
US20090234000A1 (en) 2009-09-17
EP1659125B1 (en) 2010-06-02
US6777441B2 (en) 2004-08-17
EP1330459B1 (en) 2006-08-02
ATE469907T1 (de) 2010-06-15
EP1330459A2 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
JP2009102371A (ja) 自己免疫疾患および炎症障害の処置のためのトリプトリドアナログ
JP2004525082A5 (https=)
US6670398B2 (en) Compounds and methods for treating transplant rejection
AU2001296542A1 (en) Triptolide analogs for the treatment of autoimmune and inflammatory disorders
KR20030031500A (ko) 1,3-비스-(치환된-페닐)-2-프로펜-1-온 및 ｖｃａｍ-1매개된 질환을 치료하기 위한 그의 용도
US9457004B2 (en) Opsin-binding ligands, compositions and methods of use
WO1990008539A1 (en) Myo-inositol analogs and methods for their use
JPS5916881A (ja) 血糖低下活性を有する、脂環式置換されたオキサゾリジン−２，４−ジオン
US7271274B2 (en) Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
US20040204394A1 (en) Triptolide analogues
CA2036920A1 (fr) Sels de metaux alcalinoterreux d'oxa-polyacides leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2768307B1 (en) Opsin-binding ligands, compositions and methods of use
JPS5935387B2 (ja) ３−アミノ−２−ヒドロキシプロパンのジ−置換フエノ−ルエ−テル類、その製法ならびに医薬用途
NO300372B1 (no) Nye <alfa>-mannosidaseinhibitorer
CN111620816A (zh) 螺桨烷类衍生物、其制备方法、药物组合物和用途
KR100618006B1 (ko) 나프티리딘 유도체
EP0096008B1 (en) (+)-cyanidan-3-ol derivatives, processes for their manufacture, pharmaceutical preparations that contain such compounds, and the use of the latter
US20100324133A1 (en) Branched Diepoxide Compounds for the Treatment of Inflammatory Disorders
AU2007237317A1 (en) Triptolide analogs for the treatment of autoimmune and inflammatory disorders
AU595397B2 (en) 4-hydroxy-4-(substituted thioalkenyl)-cyclohexane- carboxylic acids and derivatives thereof
EP2477988B1 (fr) Dérivés acétyléniques de 5-phényl-pyrazolopyridine, leur préparation et leur application en thérapeutique
CS214706B2 (cs) Způsob výroby R-jN-(2-fenyl-2-hydroxyethyl)-3-fenylpropylaminů
JPH06726B2 (ja) 含窒素テルペンアルコ−ル類及びこれを有効成分とする抗アレルギ−剤
JP2005041828A (ja) 新規セラミド誘導体とその制がん剤などへの利用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041001

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20080303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080922

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081020

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081120

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081225

TRDD Decision of grant or rejection written
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081225

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090129

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090210

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120306

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees